At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 384 enrolled

Drug / intervention

ABT-493 +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02441283

NCT02441283Phase 3Completed

Compare CT.gov

A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

AbbVie·interventional·Posted May 12, 2015·Updated Sep 21, 2020

In Brief

A Phase 3 clinical trial evaluating ABT-493 and ABT-530 for Hepatitis C. Completed, enrolled 384 participants across 42 sites in 8 countries.

Detailed Summary

This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus (HCV) infection.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHepatitis C

CountriesAustralia, Belgium, Canada, Germany, New Zealand, Puerto Rico, United Kingdom, United States

Collaborators--

Timeline

Phase 3CompletedFinished

20162017201820192020202120222023202420252026

First PostedMay 2015

Enrollment StartJun 2015

Primary CompletionOct 2019

TodayJul 2026

First PostedMay 12, 2015

Enrollment StartJun 22, 2015

Primary CompletionOct 15, 2019

TodayJul 2, 2026

Enrollment to primary: 4.3 yearsPosted 11.1 years ago

Interventions

ABT-493drug

ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.

ABT-530drug

ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.